NO2905338T3 - - Google Patents

Info

Publication number
NO2905338T3
NO2905338T3 NO14198318A NO14198318A NO2905338T3 NO 2905338 T3 NO2905338 T3 NO 2905338T3 NO 14198318 A NO14198318 A NO 14198318A NO 14198318 A NO14198318 A NO 14198318A NO 2905338 T3 NO2905338 T3 NO 2905338T3
Authority
NO
Norway
Application number
NO14198318A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2905338T3 publication Critical patent/NO2905338T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
NO14198318A 2010-06-22 2011-06-22 NO2905338T3 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731410P 2010-06-22 2010-06-22
US35731710P 2010-06-22 2010-06-22
EP11728508.0A EP2480675B1 (en) 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions

Publications (1)

Publication Number Publication Date
NO2905338T3 true NO2905338T3 (no) 2017-12-30

Family

ID=44509861

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14198318A NO2905338T3 (no) 2010-06-22 2011-06-22

Country Status (31)

Country Link
US (21) US9012717B2 (no)
EP (7) EP2568049B1 (no)
JP (15) JP5988969B2 (no)
KR (16) KR101945352B1 (no)
CN (4) CN103068993B (no)
AU (1) AU2011271046B2 (no)
BR (3) BR112012032991B1 (no)
CA (2) CA2804311C (no)
CY (5) CY1117537T1 (no)
DK (5) DK2905338T3 (no)
ES (5) ES2576928T3 (no)
HK (4) HK1168384A1 (no)
HR (5) HRP20160497T1 (no)
HU (5) HUE029692T2 (no)
IL (11) IL300712A (no)
LT (4) LT2905338T (no)
ME (5) ME02442B (no)
MX (6) MX2012015298A (no)
MY (6) MY157477A (no)
NO (1) NO2905338T3 (no)
NZ (6) NZ605758A (no)
PL (5) PL2905338T3 (no)
PT (5) PT2480675T (no)
RS (5) RS55042B1 (no)
RU (3) RU2601297C2 (no)
SG (4) SG10201504568YA (no)
SI (5) SI2905338T1 (no)
SM (3) SMT201600213B (no)
TR (1) TR201905992T4 (no)
WO (2) WO2011163314A1 (no)
ZA (5) ZA201300063B (no)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
NZ592308A (en) * 2008-09-30 2012-11-30 Ablexis Llc Non-human mammals for the production of chimeric antibodies
MX2011007660A (es) 2008-12-18 2011-08-17 Kingdon Craig R Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
PL3241435T3 (pl) * 2009-07-08 2021-12-13 Kymab Limited Modele zwierzęce i cząsteczki terapeutyczne
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
RU2724663C2 (ru) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
EP3251503B1 (en) 2010-03-31 2024-03-20 Ablexis, LLC Genetic engineering of mice for the production of chimeric antibodies
RS55042B1 (sr) * 2010-06-22 2016-12-30 Regeneron Pharma Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čoveka
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
JP6482757B2 (ja) 2010-07-26 2019-03-13 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． トランスジェニック動物および使用方法
JP6146913B2 (ja) 2010-08-02 2017-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｖｌドメインを含む結合タンパク質を作製するマウス
RU2664232C2 (ru) 2011-08-05 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной универсальной легкой цепью
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
ES2612935T3 (es) 2011-09-19 2017-05-19 Kymab Limited Anticuerpos, dominios variables y cadenas adaptados para su uso en seres humanos
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
DK2793567T3 (en) 2011-12-20 2019-04-15 Regeneron Pharma Humanized light chain mice
MY173376A (en) 2012-03-16 2020-01-21 Regeneron Pharma Mice that produce antigen?binding proteins with ph?dependent binding characteristics
BR112014022855A2 (pt) 2012-03-16 2017-07-18 Regeneron Pharma animal não humano geneticamente modificado, mamífero geneticamente modificado, e, método para fabricar um animal não humano
CA2865643A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
WO2013144567A1 (en) 2012-03-28 2013-10-03 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
KR101764800B1 (ko) 2013-02-20 2017-08-04 리제너론 파마슈티칼스 인코포레이티드 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물
HUE044003T2 (hu) * 2013-03-13 2019-09-30 Regeneron Pharma Korlátozott immunglobulin könnyûlánc-repertoárt expresszáló egerek
US9980470B2 (en) 2013-03-14 2018-05-29 Erasmus University Medical Center Antibody production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) * 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
RS59003B1 (sr) * 2013-09-18 2019-08-30 Regeneron Pharma Antitela sa histidinom modifikovanim lakim lancem i genetski modifikovane nehumane životinje koje ih generišu
ES2859373T3 (es) 2013-10-01 2021-10-01 Kymab Ltd Modelos animales y moléculas terapéuticas
WO2015103999A1 (en) * 2014-01-10 2015-07-16 Hung Alfur Fu-Hsin Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
US20150266976A1 (en) * 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
EP3151921B1 (en) 2014-06-06 2019-08-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
CN107072184A (zh) 2014-09-19 2017-08-18 瑞泽恩制药公司 嵌合抗原受体
AU2015327819B2 (en) 2014-10-03 2021-07-01 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
TWI758928B (zh) 2014-11-21 2022-03-21 美商必治妥美雅史谷比公司 抗cd73抗體及其用途
PL3233912T3 (pl) 2014-12-19 2021-12-27 Regenesance B.V. Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania
CA2971732A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
WO2016124709A1 (de) 2015-02-05 2016-08-11 Basf Se Solarkraftwerk mit einem ersten wärmeträgerkreislauf und einem zweiten wärmeträgerkreislauf
WO2016149678A1 (en) * 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
LT3303396T (lt) 2015-05-29 2023-01-10 Bristol-Myers Squibb Company Antikūnai prieš ox40 ir jų panaudojimo būdai
EA201890162A1 (ru) 2015-06-29 2018-07-31 Бристол-Маерс Сквибб Компани Антитела к cd40 с повышенной агонистической активностью
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
WO2017136734A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
MX2018010672A (es) 2016-03-04 2019-05-27 Univ Rockefeller Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
US20190284293A1 (en) 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
KR102417687B1 (ko) 2016-05-09 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 Tl1a 항체 및 그의 용도
NZ747857A (en) 2016-05-20 2023-01-27 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas
HUE061619T2 (hu) 2016-06-03 2023-07-28 Regeneron Pharma Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US20170372142A1 (en) * 2016-06-27 2017-12-28 Facebook, Inc. Systems and methods for identifying matching content
CN117683135A (zh) 2016-07-14 2024-03-12 百时美施贵宝公司 针对tim3的抗体及其用途
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
CR20210094A (es) 2016-10-13 2021-03-31 Massachusetts Inst Technology ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193)
IL308197A (en) * 2016-11-04 2024-01-01 Regeneron Pharma Non-human animals with a transgenic locus of the lambda-type light chain of immunoglobulins
SG11201906947SA (en) 2017-02-17 2019-08-27 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
SI3720279T1 (sl) 2017-12-05 2022-11-30 Regeneron Pharmaceuticals, Inc. Miši, ki imajo spremenjeno lahko verigo imunoglobulina lambda in njihova uporaba
KR20200108870A (ko) 2018-01-12 2020-09-21 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
CN111886256A (zh) 2018-03-23 2020-11-03 百时美施贵宝公司 抗mica和/或micb抗体及其用途
CA3093995A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
US11576984B2 (en) 2018-03-26 2023-02-14 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using
US11337409B2 (en) 2018-06-08 2022-05-24 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain I
IL305557A (en) 2018-06-14 2023-10-01 Regeneron Pharma Non-human animals with transgenic DH–DH rearrangement capacity, and their uses
EP3872506A4 (en) 2018-10-26 2023-01-11 Vehicle Energy Japan Inc. BATTERY MONITORING DEVICE
TW202033555A (zh) 2018-11-16 2020-09-16 美商必治妥美雅史谷比公司 抗nkg2a抗體及其用途
PE20212305A1 (es) 2019-01-22 2021-12-10 Bristol Myers Squibb Co Anticuerpos contra subunidad alfa il-7r y usos de estos
WO2020172505A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
KR20220016880A (ko) * 2019-06-05 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 카파 유전자좌에서 발현된 제한적 람다 경쇄 레퍼토리를 갖는 비-인간 동물 및 이의 용도
EP3993623A1 (en) * 2019-07-01 2022-05-11 Trianni, Inc. Transgenic mammals and methods of use thereof
IL293330A (en) 2019-12-02 2022-07-01 Regeneron Pharma mhc ii peptide protein structures and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
JP2023541216A (ja) * 2020-06-25 2023-09-29 ヒューマブ カンパニー リミテッド ヘテロ接合型トランスジェニック動物
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
US20240065239A1 (en) 2020-12-16 2024-02-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
AU2021410655A1 (en) 2020-12-23 2023-06-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
CA2722378C (en) * 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) * 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) * 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
EP1632571B1 (en) * 2001-05-11 2012-11-28 Kyowa Hakko Kirin Co., Ltd. Human artificial chromosome containing human antibody Lambda light chain and non-human animal containing the human artificial chromosome capable of genetic transmission
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1461442B1 (en) * 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
CA2532117C (en) 2003-07-15 2012-07-10 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
ZA200701656B (en) * 2004-08-05 2008-09-25 Genentech Inc Humanized anti-cment antagonists
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
ES2359567T3 (es) * 2004-12-29 2011-05-24 Yuhan Corporation Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa.
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US8084024B2 (en) * 2006-08-22 2011-12-27 G2 Inflammation Pty Ltd Method for producing antibodies
LT2769992T (lt) 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
WO2009129247A2 (en) * 2008-04-14 2009-10-22 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2288623B1 (en) * 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
NZ592308A (en) 2008-09-30 2012-11-30 Ablexis Llc Non-human mammals for the production of chimeric antibodies
MX2011007660A (es) * 2008-12-18 2011-08-17 Kingdon Craig R Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
PL3241435T3 (pl) * 2009-07-08 2021-12-13 Kymab Limited Modele zwierzęce i cząsteczki terapeutyczne
RU2724663C2 (ru) * 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
RS55042B1 (sr) 2010-06-22 2016-12-30 Regeneron Pharma Miševi koji ispoljavaju laki lanac hibridnog imunoglobulina sa promenljivim regionom čoveka

Also Published As

Publication number Publication date
MX336344B (es) 2016-01-15
JP2019033765A (ja) 2019-03-07
SG186391A1 (en) 2013-01-30
BR112012033248A2 (pt) 2017-11-28
HUE044001T2 (hu) 2019-09-30
RS56589B1 (sr) 2018-02-28
JP2016010417A (ja) 2016-01-21
KR102320944B1 (ko) 2021-11-04
CN103068993B (zh) 2016-01-06
ES2646052T3 (es) 2017-12-11
IL244450A (en) 2017-11-30
ME02902B (me) 2018-04-20
EP2480676A1 (en) 2012-08-01
US9226484B2 (en) 2016-01-05
KR101970944B1 (ko) 2019-04-23
US20150351371A1 (en) 2015-12-10
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
SI2480676T1 (sl) 2016-10-28
AU2011271043A1 (en) 2013-01-31
JP6009441B2 (ja) 2016-10-19
US9066502B2 (en) 2015-06-30
KR20130027555A (ko) 2013-03-15
EP2568049B1 (en) 2016-04-13
JP7236409B2 (ja) 2023-03-09
PT3034608T (pt) 2019-05-28
SMT201600229B (no) 2016-08-31
JP6545773B2 (ja) 2019-07-17
US9163092B2 (en) 2015-10-20
US9206261B2 (en) 2015-12-08
US20160060359A1 (en) 2016-03-03
EP2480676B1 (en) 2016-04-06
CA2804311A1 (en) 2011-12-29
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
ES2570131T3 (es) 2016-05-17
ME02444B (me) 2016-09-20
SG10201504324UA (en) 2015-07-30
US9394373B2 (en) 2016-07-19
US20130326647A1 (en) 2013-12-05
AU2011271046A1 (en) 2013-01-31
CA2803864A1 (en) 2011-12-29
CN103068993A (zh) 2013-04-24
IL244450A0 (en) 2016-04-21
WO2011163314A1 (en) 2011-12-29
DK2480675T3 (en) 2016-08-01
MY194456A (en) 2022-11-30
MX347318B (es) 2017-04-21
JP6243384B2 (ja) 2017-12-06
KR20190073584A (ko) 2019-06-26
US9012717B2 (en) 2015-04-21
US9150662B2 (en) 2015-10-06
HRP20160865T1 (hr) 2016-10-07
US9029628B2 (en) 2015-05-12
EP2568049A1 (en) 2013-03-13
JP2022066449A (ja) 2022-04-28
SI2480675T1 (sl) 2016-08-31
KR102462042B1 (ko) 2022-11-03
JP5988969B2 (ja) 2016-09-07
MY195217A (en) 2023-01-11
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
HK1226766A1 (zh) 2017-10-06
JP2017012204A (ja) 2017-01-19
KR20220150430A (ko) 2022-11-10
US9035128B2 (en) 2015-05-19
DK2905338T3 (da) 2017-11-06
TR201905992T4 (tr) 2019-05-21
PL2568049T3 (pl) 2017-03-31
CY1119478T1 (el) 2018-03-07
KR20210134424A (ko) 2021-11-09
SG186390A1 (en) 2013-01-30
US20150173332A1 (en) 2015-06-25
NZ707198A (en) 2016-04-29
CN104404050B (zh) 2018-06-08
KR102118565B1 (ko) 2020-06-03
RU2601297C2 (ru) 2016-10-27
US9006511B2 (en) 2015-04-14
JP2021061863A (ja) 2021-04-22
US9334333B2 (en) 2016-05-10
US20130323790A1 (en) 2013-12-05
ME02440B (me) 2016-09-20
HRP20190807T1 (hr) 2019-08-23
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
US10266803B2 (en) 2019-04-23
EP3034608A1 (en) 2016-06-22
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
EP3205726A1 (en) 2017-08-16
US9206262B2 (en) 2015-12-08
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
NZ626979A (en) 2015-05-29
PL2905338T3 (pl) 2018-01-31
ME02442B (me) 2016-09-20
NZ627119A (en) 2015-05-29
AU2011271046B2 (en) 2015-10-01
US20150089680A1 (en) 2015-03-26
HK1183321A1 (zh) 2013-12-20
HUE029691T2 (en) 2017-03-28
LT2480675T (lt) 2016-10-10
CY1118126T1 (el) 2017-06-28
PL3034608T3 (pl) 2019-08-30
BR112012032991B1 (pt) 2021-08-10
CY1117537T1 (el) 2017-04-26
IL259965A (en) 2018-07-31
ZA201300062B (en) 2014-09-25
IL282872A (en) 2021-06-30
US20190203171A1 (en) 2019-07-04
BR112012032991A2 (pt) 2015-10-06
EP2480675A1 (en) 2012-08-01
MY165287A (en) 2018-03-21
EP3456832A1 (en) 2019-03-20
JP6341972B2 (ja) 2018-06-13
RS55037B1 (sr) 2016-12-30
EP2905338B8 (en) 2018-01-24
SI2568049T1 (sl) 2016-10-28
IL255179B (en) 2018-06-28
KR20200143511A (ko) 2020-12-23
KR20200064166A (ko) 2020-06-05
JP2013532974A (ja) 2013-08-22
AU2011271043B2 (en) 2015-10-01
KR102001430B1 (ko) 2019-07-18
EP3034608B1 (en) 2019-01-30
IL247386A (en) 2017-07-31
CY1117692T1 (el) 2017-05-17
KR20210073609A (ko) 2021-06-18
KR102506001B1 (ko) 2023-03-07
SG10201504568YA (en) 2015-07-30
IL291301A (en) 2022-05-01
JP2020062061A (ja) 2020-04-23
RS58736B1 (sr) 2019-06-28
US20150320023A1 (en) 2015-11-12
IL259965B (en) 2019-02-28
DK2568049T3 (en) 2016-08-01
KR101945352B1 (ko) 2019-02-07
IL223720A (en) 2017-05-29
HRP20160794T1 (hr) 2016-08-12
IL255179A0 (en) 2017-12-31
MX347322B (es) 2017-04-21
HRP20171666T1 (hr) 2017-12-15
PL2480676T3 (pl) 2016-10-31
MY157477A (en) 2016-06-15
PT2480676E (pt) 2016-06-09
JP2018023403A (ja) 2018-02-15
KR20190142436A (ko) 2019-12-26
JP2020128440A (ja) 2020-08-27
RU2013102595A (ru) 2014-07-27
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
AU2011271043A8 (en) 2016-01-21
US9540452B2 (en) 2017-01-10
CN104342455A (zh) 2015-02-11
US20120070861A1 (en) 2012-03-22
ZA201404601B (en) 2016-02-24
RU2590594C2 (ru) 2016-07-10
JP2013531501A (ja) 2013-08-08
PT2480675T (pt) 2016-07-11
US9850462B2 (en) 2017-12-26
KR20190049932A (ko) 2019-05-09
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
BR112012032991A8 (pt) 2020-09-29
JP6963542B2 (ja) 2021-11-10
RS55042B1 (sr) 2016-12-30
RU2016119423A3 (no) 2019-11-19
HK1170766A1 (zh) 2013-03-08
KR20190014578A (ko) 2019-02-12
CY1122877T1 (el) 2021-05-05
US9844212B2 (en) 2017-12-19
HUE030285T2 (en) 2017-05-29
CN103068994B (zh) 2016-01-20
MY195214A (en) 2023-01-11
US20170258059A1 (en) 2017-09-14
IL291301B1 (en) 2023-03-01
ZA201300063B (en) 2014-09-25
KR102193823B1 (ko) 2020-12-22
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
KR20180135997A (ko) 2018-12-21
US20150176002A1 (en) 2015-06-25
US20150173331A1 (en) 2015-06-25
SI3034608T1 (sl) 2019-06-28
KR101991234B1 (ko) 2019-06-20
US20150246977A1 (en) 2015-09-03
HRP20160497T1 (hr) 2016-07-15
EP2480675B1 (en) 2016-04-06
ME03386B (me) 2020-01-20
RS54891B1 (sr) 2016-10-31
SMT201600212B (it) 2016-08-31
HUE029692T2 (en) 2017-03-28
US20140137275A1 (en) 2014-05-15
ES2576928T3 (es) 2016-07-12
US20200239837A1 (en) 2020-07-30
ZA201506598B (en) 2017-03-29
JP2017006152A (ja) 2017-01-12
MX2022002117A (es) 2022-03-17
SMT201600213B (it) 2016-08-31
US20180064078A1 (en) 2018-03-08
DK2480676T3 (en) 2016-06-20
IL223719A (en) 2016-10-31
US20160057979A1 (en) 2016-03-03
MX348942B (es) 2017-07-04
DK3034608T3 (da) 2019-05-06
LT2905338T (lt) 2017-12-27
KR101934852B1 (ko) 2019-01-04
JP2018201527A (ja) 2018-12-27
RU2724736C2 (ru) 2020-06-25
NZ605751A (en) 2014-10-31
KR20230036157A (ko) 2023-03-14
IL291301B2 (en) 2023-07-01
US20190153384A1 (en) 2019-05-23
HUE036597T2 (hu) 2018-07-30
US9399683B2 (en) 2016-07-26
IL300712A (en) 2023-04-01
US20170107484A1 (en) 2017-04-20
KR20210013376A (ko) 2021-02-03
JP2018201528A (ja) 2018-12-27
IL269078A (en) 2019-11-28
AU2011271043A9 (en) 2015-10-01
BR122020013427B1 (pt) 2021-08-03
EP2905338B1 (en) 2017-08-02
JP6073441B2 (ja) 2017-02-01
NZ605758A (en) 2014-08-29
KR20180135996A (ko) 2018-12-21
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
ZA201404600B (en) 2015-09-30
KR102059909B1 (ko) 2019-12-27
JP2016010415A (ja) 2016-01-21
KR102211911B1 (ko) 2021-02-05
MX2012015300A (es) 2013-05-01
US20150246976A1 (en) 2015-09-03
CN103068994A (zh) 2013-04-24
MY195212A (en) 2023-01-11
RU2013102596A (ru) 2014-07-27
CN104342455B (zh) 2017-05-31
CN104404050A (zh) 2015-03-11
EP2905338A1 (en) 2015-08-12
JP2023133554A (ja) 2023-09-22
NZ707200A (en) 2016-04-29
CA2803864C (en) 2017-05-16
CA2804311C (en) 2017-09-12
SI2905338T1 (sl) 2017-12-29

Similar Documents

Publication Publication Date Title
BR122017007260A2 (no)
BR112013013385A2 (no)
BR112013008959A2 (no)
NO2905338T3 (no)
BR112012031500A2 (no)
BR112012029986A2 (no)
BR112012028408A2 (no)
BR112012026492A2 (no)
BR112012024897A2 (no)
BR112012019354A2 (no)
BR112012025307A2 (no)
BR112012026946A2 (no)
BR112012017960A2 (no)
BR112012025482A2 (no)
BR112013006400A2 (no)
BR112012031826A2 (no)
BR112012025577A2 (no)
BR112012016456A2 (no)
BR112012025308A2 (no)
BR112012018256A2 (no)
BR112012027945A2 (no)
BR112012024872A2 (no)
BR112012023265A2 (no)
BR112013010949A2 (no)
BR112012026403A2 (no)